Lagevrio (molnupiravir) Provider Guidance

Eligibility

- Mild-moderate COVID-19 within 5 days of symptom onset
- Risk of progression to severe COVID-19, a list of qualifying conditions can be found in Appendix H of SARS CoV-2 guidance
- Age ≥18 years old

Dosing

- 800 mg (four 200 mg capsules) by mouth twice daily x 5 days
- No renal or hepatic adjustments are required

No lab monitoring is required

Contraindications for use

- History of clinically significant hypersensitivity reactions to molnupiravir
- Pregnancy

Use in specific populations

- Patients of childbearing potential should be counseled to use a reliable method of contraception for the duration of therapy and for 4 days after completing molnupiravir treatment
  - Males of reproductive potential who are sexually active with individuals of childbearing potential should use a reliable method of contraception for the duration of treatment and for at least 3 months after the last dose of molnupiravir
- Breastfeeding is not recommended during treatment
  - A lactating individual may consider interrupting breastfeeding but continue to pump and discard breast milk during treatment and for 4 days after the last dose of molnupiravir

Common adverse reactions (incidence ≥1%)

- Diarrhea, nausea, and dizziness

Drug interactions

- No drug interactions have been identified based on the limited available data on the EUA
  - Molnupiravir’s EAU fact sheet for health care providers

More information

- University of Iowa Health Care Guidance on Treatment Options for Patients with SARS-CoV-2 Appendix H